SPNGNX_logo_hrz.jpg
Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)
January 05, 2021 05:00 ET | Spinogenix, Inc.
SAN DIEGO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Spinogenix, Inc. a preclinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced...
Zhittya Logo.jpg
Zhittya Genesis Medicine Announces It Has Been Approved to Initiate Clinical Trials in Mexico for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
October 15, 2020 10:30 ET | Zhittya Genesis Medicine Inc
LAS VEGAS, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (Zhittya), a private company, announces that it will initiate clinical trials in Mexico to test a medical hypothesis that...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences to Highlight Preclinical ADAR Editing Data and Neurology Programs at TIDES and OTS Annual Meetings
September 15, 2020 07:30 ET | Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 10, 2020 16:25 ET | Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
AZ Logo.png
AZTherapies Doses First Patient in Phase 2a Study of ALZT-OP1a in Amyotrophic Lateral Sclerosis (ALS)
September 09, 2020 08:34 ET | AZTherapies, Inc.
BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the dosing of the first...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences to Highlight PRISM Platform Advancements and Preclinical Neurology Pipeline During Analyst and Investor Research Webcast
August 06, 2020 08:00 ET | Wave Life Sciences USA, Inc.
Neurology pipeline discussion will include new preclinical data for C9orf72 program for ALS and FTD Platform advancements to be shared include new in vivo RNA editing data Live webcast scheduled for...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences to Webcast Conference Call of Second Quarter 2020 Financial Results on August 10, 2020
July 27, 2020 16:05 ET | Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Logo transparent PNG.png
PathMaker Neurosystems Welcomes Healthcare Veteran Terri Bresenham to Board of Directors
July 15, 2020 07:00 ET | PathMaker Neurosystems Inc.
BOSTON and PARIS, July 15, 2020 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neuromodulation company developing breakthrough non-invasive technology for the...
Biogen_Logo_Standard-rgb_R.jpg
The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS
July 08, 2020 17:01 ET | Biogen Inc.
Tofersen is an investigational molecule for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), the second most common genetic form of ALS, a progressive neurodegenerative diseaseFinal...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences to Present at the Jefferies 2020 Virtual Healthcare Conference
May 26, 2020 16:05 ET | Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...